Immunome, Inc
Price
FilingsNewest: 8-K, Material agreementOct 5 →Insiders3 insiders bought $2.3M in 11 open-market buys. 5 insiders sold $12.6M, 6 of 10 sales on a 10b5-1 plan.→HoldersFMR 15.0%BlackRock 7.8%State Street 4.8%→PeersClosest companies: BDTX, TYRA, TPST→
From the filings
Figures
- Revenue
- $0.00last 12 months
- Net income
- −$254.3Mlast 12 months
- Operating cash flow
- −$196.5Mlast 12 months
- Cash and equivalents
- $217.7Mat the last balance sheet
- Shares outstanding
- 113.4M shareson issue